TDC
IRD

Thompson Davis & Co’s Opus Genetics IRD Stock Holding History

Thompson Davis & Co’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,000
Closed -$57K – 141
2023
Q3 		$57K Sell
17,000
-1,188
-7% -$4.77K 0.07% 93
2023
Q2 		$78.9K Buy
+18,188
New +$86.4K 0.09% 104

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thompson Davis & Co's IRD Position: Q4 2023 in Review

Thompson Davis & Co sold out of Opus Genetics (IRD) in Q4 2023, closing a stake of 17,000 shares — an estimated $57K sold.

Thompson Davis & Co first reported a position in IRD in Q2 2023 and held it in 2 quarters. The position peaked at $78.9K in Q2 2023. 50 funds tracked by Wall St. Rank hold IRD as of Q4 2023.

  • Thompson Davis & Co reported no remaining Opus Genetics position as of Q4 2023 after selling out during the quarter.
  • Thompson Davis & Co sold 17,000 Opus Genetics shares in Q4 2023, an estimated $57K.
  • Thompson Davis & Co first reported a position in Opus Genetics in Q2 2023 and held it in 2 quarters.
  • Thompson Davis & Co's Opus Genetics position peaked at $78.9K in Q2 2023.
  • 50 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2023.

Based on Thompson Davis & Co's 13F filing for Q4 2023, filed 5 Feb 2024.